As last year, we were present in Biofit. This congress is one of the best european place to be for B2B meetings. I had around 20 B to B meetings to discuss partnering and business, with biotech companies, other CROs and with public transfert technology societies as SATT in France or ErasmusMC in The Netherlands. That I can observe is that B2B meetings with pharmaceutical industries are increasingly turned to partnering around drugs already in clinical development rather than business around innovative projects. Nevertheless, it was a good place to discuss partnering with others CROs and biotech companies.
english
SLAS Washington 2019: the evidence of 3D culture for drug discovery!
We were really happy to participate in SLAS2019 in Washington last week. In addition to spending a few relaxing days in Washington, we enjoyed the warm welcome of the US team of Molecular Devices. We Read more…
